Objective: Evaluation of the effects of camel milk and cow milk on blood glucose, HbA1c, lipid profile, blood insuline and insuline dose in patients with diabetes treated with glargine. Design: Randomized Setting and conduct: A- Participants including major eligibility criteria - Major inclusion criteria: Patients with diabetes treated with glargine - Major exclusion criteria: having cardiovascular and renal diseases - Sample size: 40 B- Intervention: 500 cc camel milk or caw milk C- Intervention Time: 3 months D- Main outcome: Blood sugar, HbA1c, lipid profile, blood insuline and insuline dose
General information
Acronym
IRCT registration information
IRCT registration number:IRCT201310094794N10
Registration date:2016-03-02, 1394/12/12
Registration timing:registered_while_recruiting
Last update:
Update count:0
Registration date
2016-03-02, 1394/12/12
Registrant information
Name
Fereidoun Azizi
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 21 2240 9309
Email address
azizi@endocrine.ac.ir
Recruitment status
Recruitment complete
Funding source
Vice chancellor for Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences
Expected recruitment start date
2015-08-23, 1394/06/01
Expected recruitment end date
2016-03-19, 1394/12/29
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Effect of camel milk on glycemic control and lipid profile of diabetic patients treated with long-acting insulin
Public title
camel milk and diabetes
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion Criteria: Patients with diabetes treated with glargine; age range: 30 to 70 years old. Exclusion Criteria:pregnancy or lactation; smoking and alcohol consumption; Lactose intolerance; having cardiovascular disease, liver, lung, kidney and Chronic gastrointestinal and thyroid dysfunction; following from the weight loss diets two months prior to study; weight changes (increase or decrease) more than 5 kg two months prior to study
Age
From 30 years old to 70 years old
Gender
Both
Phase
N/A
Groups that have been masked
No information
Sample size
Target sample size:
40
Randomization (investigator's opinion)
Randomized
Randomization description
Blinding (investigator's opinion)
Not blinded
Blinding description
Placebo
Used
Assignment
Parallel
Other design features
Secondary Ids
empty
Ethics committees
1
Ethics committee
Name of ethics committee
Ethics committee, Research Institute For Endocrine Sciences, Shahid Beheshti University of Medical S